What is Celestial Biolabs share price return in the past 10 years?

Celestial Biolabs Ltd share price has declined -18.2% annually (CAGR) over the past ten years.

Celestial Biolabs Ltd - Stock Valuation and Financial Performance

Name: Celestial Biolabs
Brand: Celestial Biolabs

BSE: 532871 | NSE: CELESTIAL | Pharmaceuticals & Drugs | Small Cap

Place order

DeciZen - make an informed investing decision on Celestial Biolabs

Based on:

Data

M-Cap below 100cr DeciZen not available

Celestial Biolabs stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

4.6 Cr.

52-wk low:

52-wk high:

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

The key valuation ratios of Celestial Biolabs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is a good buy now?

No data found

10 Year X-Ray of Celestial Biolabs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	TTM
ROCE % ⓘ	1.3%	2.4%	4.2%	3%	3.2%	3.2%	0.7%	-125.8%	-1.1%	-2.5%	-
Value Creation Index ⓘ	-0.9	-0.8	-0.7	-0.8	-0.8	-0.8	-1.0	-10.0	-1.1	-1.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	21.2	23.5	27.5	32.9	38.7	42.8	49	5.2	0	0.2	0
Sales YoY Gr.	-	11.1%	16.8%	19.7%	17.7%	10.7%	14.4%	-89.3%	-100%	NA	-
Adj EPS ⓘ	0.5	0.5	0.7	1	1.5	1.5	-0	-36.9	-0.1	-0.2	-0.3
YoY Gr.	-	0%	42.9%	45.7%	45.1%	3.4%	-100.7%	NA	NA	NA	-
BVPS (₹) ⓘ	54.3	49.3	43.6	44	43.8	45.3	45.3	1.7	1.7	1.5	1.4
Adj Net Profit ⓘ	0.7	0.8	1.3	2.1	3.3	3.5	0	-83.3	-0.2	-0.4	-1
Cash Flow from Ops. ⓘ	4.5	3.3	5.8	8	13.4	3.3	16.7	-3.1	0	-0.3	-
Debt/CF from Ops. ⓘ	3.4	5.6	1.9	1	0.6	2.9	0.8	-3.7	-329.9	-41.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-42.3%	-67.1%	-85.5%	NA
Adj EPS ⓘ	-189.5%	-165.6%	NA	NA
BVPSⓘ	-33%	-49.2%	-68%	-10.8%
Share Price	-18.2%	-15.4%	6.4%	20.3%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	TTM
Return on Equity % ⓘ	0.9	1	1.5	2.3	3.4	3.4	-0	-156.9	-4.5	-11.5	-18.8
Op. Profit Mgn % ⓘ	26.9	33	45.3	26	18.1	27.6	24	-1428.1	0	-229.2	-273.2
Net Profit Mgn % ⓘ	3.4	3.6	4.7	6.3	8.6	8.1	-0.1	-1593.9	0	-277.6	-321
Debt to Equity ⓘ	0.2	0.2	0.1	0.1	0.1	0.1	0.1	2.9	3	3.4	-
Working Cap Days ⓘ	551	587	583	517	308	208	201	935	0	10,478	5,008
Cash Conv. Cycle ⓘ	178	207	240	234	171	169	170	868	0	9,096	-1,603

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Celestial Biolabs Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-0.3	-
TTM Sales (₹ Cr.)	0.2	-
BVPS (₹.) ⓘ	1.4	-
Reserves (₹ Cr.) ⓘ	-19	-
P/BV ⓘ	1.46	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	2.02 / 2.02
All Time Low / High (₹)	1.99 / 78.25
Market Cap (₹ Cr.)	4.6
Equity (₹ Cr.)	22.6
Face Value (₹)	10
Industry PE ⓘ	47.9

Management X-Ray of Celestial Biolabs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Celestial Biolabs

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Celestial Biolabs

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Sales	21.16	23.50	27.45	32.86	38.66	42.81	48.97	5.23	0	0.15
Operating Expenses ⓘ	15.47	15.75	15.02	24.30	31.67	30.99	37.24	101.33	0.16	0.49
Manufacturing Costs	1.50	1.40	1.88	4.42	4.87	1	0.62	0.05	0.02	0.04
Material Costs	8.62	8.87	5.43	16.04	24.38	28.64	28.49	3.27	0	0.06
Employee Cost	1.01	0.76	-11,998.99	0.92	1.08	0.63	1.48	0.27	0.03	0.12
Other Costs ⓘ	4.33	4.73	12,006.70	2.92	1.34	0.71	6.65	97.74	0.11	0.26
Operating Profit ⓘ	5.69	7.75	12.43	8.56	7	11.83	11.74	-96.10	-0.16	-0.34
Operating Profit Margin (%)	26.9%	33.0%	45.3%	26.0%	18.1%	27.6%	24.0%	-1,838.1%	-	-229.0%
Other Income ⓘ	0.04	0	0	0.29	0	0	0.36	0.04	0.03	0
Interest ⓘ	0.69	2.22	4.15	1.29	0.02	0.03	1.25	1.43	0	0.04
Depreciation ⓘ	4.73	4.98	7.06	5.71	3.30	7.70	9.44	2.26	0.04	0.03
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0.31	0.55	1.23	1.85	3.67	4.11	1.40	-99.75	-0.17	-0.41
Tax ⓘ	-0.40	-0.29	-0.07	-0.23	0.34	0.65	1.43	-1.41	0	0
Profit After Tax	0.71	0.84	1.30	2.08	3.33	3.46	-0.03	-98.34	-0.17	-0.41
PAT Margin (%)	3.3%	3.6%	4.7%	6.3%	8.6%	8.1%	-0.1%	-1,880.9%	-	-277.0%
Adjusted EPS (₹)	0.5	0.5	0.7	1.0	1.5	1.5	0.0	-43.5	-0.1	-0.2
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Equity and Liabilities
Shareholders Fund	79.26	85.60	80.81	90.06	98.84	102.30	102.27	3.93	3.76	3.35
Share Capital ⓘ	14.60	17.35	18.56	20.49	22.59	22.59	22.59	22.59	22.59	22.59
Reserves ⓘ	64.66	68.25	62.25	69.57	76.26	79.71	79.69	-18.66	-18.83	-19.24
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	15.22	18.44	11.17	8.25	8.25	4.82	7.82	8.18	11.28	11.54
Long Term Debt	15.22	18.44	11.17	8.25	8.25	4.82	7.82	8.18	8.23	8.49
Short Term Debt	0	0	0	0	0	0	0	0	3.05	3.05
Trade Payables	0.26	0.37	0.65	0.69	0.42	0.43	0.56	0.34	0.38	0.26
Others Liabilities ⓘ	0.57	0	6.48	6	1.03	6.40	8.68	4.80	1.75	2.03
Total Liabilities ⓘ	95.32	104.42	99.11	104.99	108.55	113.95	119.33	17.25	17.17	17.18
Fixed Assets
Gross Block	53.38	63.36	61.39	65.75	103.46	102.55	110.41	11.84	11.84	11.85
Accumulated Depreciation	14.08	26.54	33.60	39.31	42.61	49.45	58.89	11.67	11.71	11.74
Net Fixed Assetsⓘ	39.30	36.82	27.78	26.45	60.85	53.10	51.51	0.17	0.13	0.10
CWIP ⓘ	22.62	24.68	25.19	29.56	29.56	29.56	45.24	12.82	12.82	12.82
Investmentsⓘ	0	0	0	0.30	0.30	0	0	0	0	0
Inventories	5.30	7.27	12.71	9.66	7.72	3.96	6.14	0.05	0.05	0.05
Trade Receivables	5.79	9.04	9	11.95	8.25	20.77	15.64	3.83	3.78	3.83
Cash Equivalents	0.17	0.55	0.85	0.92	0.41	0.01	0.05	0.01	0.02	0
Others Assetsⓘ	22.14	26.06	23.59	26.15	1.46	6.56	0.76	0.37	0.38	0.38
Total Assets ⓘ	95.32	104.42	99.11	104.99	108.55	113.95	119.33	17.25	17.17	17.18

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Cash Flow From Operating Activity ⓘ	4.48	3.27	5.79	8.02	13.40	3.34	16.65	-3.06	-0.03	-0.28
PBT ⓘ	0.31	0.55	1.23	1.85	3.67	4.11	1.40	-99.75	-0.17	-0.41
Adjustment ⓘ	5.82	7.49	11.27	7.12	2.98	7.07	10.69	81.11	0.04	0.03
Changes in Working Capital ⓘ	-1.65	-4.77	-6.71	-0.95	6.75	-7.84	4.55	15.58	0.1	0.1
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	-6.36	-8.19	-3.60	-11.61	-13.89	-4.88	-18.66	4.09	0	0
Capex	-3.53	-2.50	-3.10	-0.89	0	0	0	4.09	0	0
Net Investments	0	0	0	-0.30	0	0	0	0	0	0
Others ⓘ	-2.83	-5.69	-0.50	-10.42	-13.89	-4.88	-18.65	0	0	0
Cash Flow From Financing Activityⓘ	1.89	5.30	-1.88	3.66	-0.02	1.14	2.05	-1.07	0.05	0.26
Net Proceeds from Shares ⓘ	0	5.50	1.21	1.93	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	1.17	3	0.36	0.05	0.26
Interest Paid ⓘ	-0.69	-2.22	-4.15	-1.19	-0.02	-0.03	-1.25	-1.43	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	2.57	2.01	1.06	2.92	0	0	0.30	0	0	0
Net Cash Flow ⓘ	0	0.38	0.30	0.07	-0.51	-0.40	0.04	-0.04	0.01	-0.02

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Ratios
ROE (%)	0.9	1.02	1.56	2.43	3.53	3.44	-0.03	-185.19	-4.46	-11.52
ROCE (%)	1.07	2.79	5.33	3.12	3.5	3.78	2.33	-150.19	-1.13	-2.46
Asset Turnover Ratio	0.23	0.24	0.27	0.32	0.36	0.38	0.42	0.08	0	0.01
PAT to CFO Conversion(x)	6.31	3.89	4.45	3.86	4.02	0.97	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	95	115	120	116	95	124	136	679	0	9,419
Inventory Days	88	98	133	124	82	50	38	216	0	125
Payable Days	10	13	34	15	8	5	6	50	0	1,878

Celestial Biolabs Ltd Stock News

Celestial Biolabs Ltd FAQs

What is the share price of Celestial Biolabs?

Company share prices are keep on changing according to the market conditions. The closing price of Celestial Biolabs on 11-Mar-2020 18:01 is ₹2.43.

What is the market cap of Celestial Biolabs?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 11-Mar-2020 18:01 the market cap of Celestial Biolabs stood at ₹4.56.

What is the P/E ratio of Celestial Biolabs?

The latest P/E ratio of Celestial Biolabs as of 11-Mar-2020 18:01 is 0.00.

What is the P/B ratio of Celestial Biolabs?

The latest P/B ratio of Celestial Biolabs as of 11-Mar-2020 18:01 is 1.46.

What is the 52-week high and low of Celestial Biolabs?

The 52-week high of Celestial Biolabs is ₹2.02 and the 52-week low is ₹2.02.

What is the TTM revenue of Celestial Biolabs?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Celestial Biolabs is ₹0.19 ( Cr.) .

About Celestial Biolabs Ltd

Celestial Labs Limited was incorporated as a Private Limited Company on November 19, 1997 as Celestial Technologies Private Limited. The company was later converted into a Public Limited Company under the name Celestial Technologies Limited'on December 6, 1999 and has been subsequently renamed as Celestial Labs Limited effective from February 13, 2004.

Celestial Labs ( CLL ) has been supporting Pharma, Bio-pharma and Biotech manufacturing with customized ITsolutions and contract research. CLL also involved in the R&D, commercial production and marketing of enzymes, nutraceuticals.Celestial Labs is setting up a biotechnology facility in Genome Valley at Hyderabad, India to manufacture its own drug molecules, industrial enzymes and to contract research activities.

Celestial Labs Ltd (CLL) is an ISO 9001-2001 certified company with a decade of experience in Insilico Drug Discovery and Development, and contract research services.Celestial Labs is recognized by DSIR (Government of India) for its R&D endeavors in the Insilco Drug Discovery software development. Celestial has been providing customized solutions and services in Bio-IT as well as research services over a decade.

The business plan of Celestial Labs is essentially based on the production and supply of the biotechnological products which have very significant industrial implications, especially in both Pharma and Bio-pharmaceutical sectors. The plan is envisaged after a thorough ground-work in terms of building up of a technology base through stake holders and collaborators, further supported by market analysis and import-export imperatives. Celestial's ambitious goals earmarked with well-worked road map, strategic implementation and management tools are well supported by its competent and experienced personnel to effectively carry out the scientific, engineering, finance and management functions of its project activities.

Products and services offered by the company:Products: